Agios Pharmaceuticals | AGIO - Cost Of Sales


Agios Pharmaceuticals reported $1.32M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
AbbVie USD 4.29B 73M Jun/2026
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
Alnylam Pharmaceuticals USD 298.45M 87.33M Jun/2026
Amgen USD 1.87B 271M Jun/2026
Astellas Pharma JPY 158.38B 28.94B Jun/2026
AstraZeneca USD 2.52B 2.73B Jun/2026
Bayer EUR 4.54B 692M Jun/2026
Biogen USD 945.1M 147.6M Jun/2026
BioMarin Pharmaceutical USD 276.29M 76.8M Jun/2026
Bristol-Myers Squibb USD 7.89B 4.03B Jun/2026
Daiichi Sankyo JPY 124.29B 6.02B Jun/2026
Eli Lilly USD 3.27B 309M Jun/2026
Exelixis USD 20.66M 704K Jun/2026
Gilead Sciences USD 1000M 445M Jun/2026
GlaxoSmithKline GBP 2.07B 192M Jun/2026
Incyte USD 104.96M 457K Jun/2026
Ionis Pharmaceuticals USD 2.74M 261K Jun/2026
Merck USD 3.14B 200M Jun/2026
Moderna USD 93M 862M Jun/2026
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Novartis USD 3.71B 251M Jun/2026
Novartis USD 3.46B 83M Mar/2026
Pfizer USD 4.09B 498M Jun/2026
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Regeneron Pharmaceuticals USD 576.5M 92.9M Jun/2026
Roche Holding CHF 7.85B 630M Jun/2026
Sarepta Therapeutics USD 150.1M 40.64M Jun/2026
Vertex Pharmaceuticals USD 489.2M 96.4M Jun/2026